DailyIQ
Last updatedjust now

GMED·Globus Medical Inc. Class A

$76.40
-0.17 (-0.22%)
After Hours
High
$77.65
Open
$77.01
Market Cap
10.15B
52W High
$101.40
Low
$75.84
P. Close
$76.40
P/E
18.96
52W Low
$56.32
Fwd P/E
14.18
DailyIQ Est.
$104.13
Inst. Ownership
-
Short Interest
5.10%
Days to Cover
4.6
Technical Score (1D)
55
BULLISH
News Sentiment
64
BULLISH
On Oct 6, 2026, Zacks highlighted Globus Medical (GMED) in its industry outlook on generative AI adoption. The report noted that GMED was moving from experimental to practical applications of GenAI, using the technology to generate synthetic medical images, simulate disease progression, and design potential drug molecules. It emphasized that more than 80 % of U.S. healthcare leaders had deployed GenAI use cases, positioning GMED to benefit from accelerated drug development and improved patient engagement. The article also discussed regulatory developments, such as the EU AI Act, as shaping the industry landscape. Overall, the piece portrayed GMED’s AI initiatives as a positive driver for future growth.
LOW TARGET
$84 +9.9%
2 analysts
MEAN TARGET
$101 +32.0%
12 analysts
HIGH TARGET
$125 +63.5%
11 analysts
PRICE RANGE
$84.00 - $125.00
SB / B / H / S / SS
4/12/7/1/1
DAILYIQ EST.
$104.13 (+36.2%)
Bought (1Y)
0 shares
$0
Sold (1Y)
80,000 shares
$6.4M
TOBIN JAMES R-
Option Exercise15,000 shares2026-09-15
TOBIN JAMES R-
Sell30,000 shares2026-09-15
TOBIN JAMES R-
Option Exercise15,000 shares2026-09-15
ZARRILLI STEPHEN T-
Option Exercise25,000 shares2026-08-18
ZARRILLI STEPHEN T-
Sell25,000 shares2026-08-18
91/ 100
Strong bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
67.4%
Net Margin
18.3%
Revenue CAGR
16.7%
Current Ratio
4.26x
Return on Equity
11.8%

EPS

EstBeatMiss
$0.72$0.85$0.99$1.12$1.26Q3'25Q3'26
QtrEstActual+/−
Q3'26$1.20 - -
Q3'25$0.78$1.18+51.1%

Revenue

EstBeatMiss
$763M$776M$789M$801M$814MQ3'25Q3'26
QtrEstActual+/−
Q3'26$808M - -
Q3'25 - $769M -

Market Data

GMED Stock Snapshot

NEUTRAL55/100
$76.43+$0.03 (0.0%)
Market cap
10.15B
P/E ratio
19.0
Day range
$75.84 – $77.65
News sentiment
64/100 · Bullish
Analyst target
$100.92 (+32.0%)
Consensus
Buy · 25 analysts
52-week range+35.7% off low · -24.6% from high
$56.32$101.40
Price $76.43 DailyIQ Est. $104.13

This is a pause rather than a turn for GMED - the signals are mixed by construction. Earnings and guidance carry more weight than macro data at this capitalisation.

Behaviour On Record

What GMED's own history says about today's numbers

Realized volatility (21d)
31.4% 59th pct
Below its peak
-22.7%
vs 200-day average
-9.6%
Up days (1y)
47%

Globus Medical Inc. Class A is currently running 31.4% annualised volatility over the last 21 sessions. Measured against GMED's own 13 years of daily returns rather than a market-wide average, that is the 59th percentile — close to its own typical level, against a typical reading of 28.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

GMED is trading -22.7% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -27.2%, and the deepest was -45.0% in 2023. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits -9.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 19th percentile — a narrower gap than it typically runs. Over the past year GMED closed higher on 47% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 13 years of records, GMED finished the month higher 9 of 13 times, with a median return of +4.7% and an average of +3.9%. Its strongest month historically has been November at +8.6% on average, its weakest September at -3.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: GMED has opened more than 2% away from the prior close in 194 of 3,267 sessions (5.9% of the time), with the largest gaps running +17.5% and -13.0%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against GMED's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of GMED's sector?

Globus Medical Inc. Class A sits in the Health Care sector, currently ranked 8th of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank
#8 of 12
Sector state
Lagging
Sector rotation score
0

Options Market

What is the options market pricing for GMED?

CallsPuts

For Globus Medical Inc. Class A's nearest expiry (2026-10-16, 10 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.25), with at-the-money implied volatility around 50.0%. The options market is pricing roughly a ±7.1% move by that expiry — a range of about $70.31–$81.07.

Put/call ratio (2026-10-16)
0.25
ATM implied volatility
50.0%
Total open interest
1,203
Expected move by 2026-10-16
±7.1% ($70.31–$81.07)

Analyst Rating Changes

Are analysts turning bullish or bearish on GMED?

RBC Capital most recently reiterated its rating on Globus Medical Inc. Class A to Outperform on Oct 1, 2026 with a price target of $85 (from $115). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
RBC Capital — Outperform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 1, 2026RBC CapitalMaintainedOutperform$115 → $85
Aug 7, 2026Wells FargoMaintainedOverweight$103 → $99
Jul 28, 2026UBSInitiatedNeutral$82
Jul 16, 2026Truist SecuritiesMaintainedBuy$115 → $100
Jul 13, 2026RBC CapitalMaintainedOutperform$120 → $115
Jul 9, 2026BMO CapitalInitiatedOutperform$94
Jul 8, 2026StifelMaintainedHold$95 → $80
Jun 15, 2026Piper SandlerMaintainedOverweight$115 → $100
May 8, 2026RBC CapitalMaintainedOutperform$115 → $120
May 8, 2026Wells FargoMaintainedOverweight$104 → $103
May 8, 2026NeedhamMaintainedBuy$114 → $117
Feb 26, 2026Wells FargoMaintainedOverweight$98 → $104

News Sentiment Analysis

Sentiment gathered from recent headlines

64/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Globus Medical demonstrated robust return on invested capital and maintained a low debt profile, underscoring its financial strength. The company’s growth trajectory appears sustainable, supported by a diversified product portfolio and expanding market presence. Analysts noted that the firm’s valuation remains attractive relative to peers, suggesting potential upside for investors. These factors collectively reinforce a positive outlook for GMED’s future performance.
What did this article say?
On October 6, 2026, Zacks highlighted Globus Medical (GMED) as part of a broader industry analysis on generative AI adoption. The report noted that GMED is moving from experimental to practical applications of GenAI, using it to generate synthetic medical images, simulate disease progression, and design potential drug molecules. The article emphasized that over 80% of U.S. healthcare leaders have deployed GenAI use cases, positioning GMED to benefit from accelerated drug development and improved patient engagement. Regulatory developments, such as the EU AI Act, were also discussed as shaping the industry landscape. Overall, the piece portrayed GMED’s AI initiatives as a positive driver for future growth.
What did this article say?
RBC Capital analyst Kendall Au reduced Globus Medical’s price target from $115 to $85 while keeping an Outperform rating. The downgrade reflects concerns about the company’s valuation relative to peers and potential earnings pressure. The move signals a negative outlook for the stock, suggesting investors may see limited upside in the near term.
What did this article say?
Zacks analysis compared Globus Medical (GMED) and Integer (ITGR) for value investors, highlighting GMED’s higher Zacks Rank of #1 (Strong Buy) versus ITGR’s #3 (Hold). The report noted GMED’s positive earnings estimate revisions and strong value metrics, suggesting an improving earnings outlook. The comparison emphasized GMED’s undervaluation relative to its peers, positioning it as a more attractive option for value-focused portfolios. The article concluded that GMED’s stronger fundamentals and valuation make it a better buy for investors seeking value opportunities.
What did this article say?
Fresenius Medical Care AG & Co. (GMED) announced a strategic shift in its China operations, concentrating on advanced in‑center dialysis and critical‑care technologies while trimming less profitable portfolio items. The company earmarked €110 million for one‑time restructuring costs and emphasized its local manufacturing and design capabilities to support the move. Management projected that the focused approach would strengthen competitive positioning and accelerate profitable growth in the Chinese dialysis market. The announcement was well received by investors, with shares rising modestly following the disclosure.
What did this article say?
Globus Medical (GMED) experienced a 10% decline in share price over the past month and a 5% drop over the past three months, drawing investor attention. The company’s 1‑year total shareholder return of 32.5% and 3‑year return of 50.8% highlight that long‑term investors have still earned substantial gains despite the recent pullback. The recent price movement suggests a temporary cooling of momentum, while the broader market context indicates that the decline may be relative to peers. The data imply a modest negative short‑term outlook, with no immediate catalyst for a deeper downturn.
What did this article say?
Globus Medical’s stock fell 10.3% over the past six months, lagging behind the S&P 500’s 21.4% gain. The decline reflects investor concerns about the company’s recent performance, despite its global presence and a portfolio of more than ten new products launched in 2023. Analysts note that constant‑currency revenue has been a positive driver, suggesting underlying demand remains resilient. The mixed signals leave the market uncertain about GMED’s near‑term trajectory.
What did this article say?
The article reviews the Q2 earnings landscape for the medical devices and supplies sector, highlighting Globus Medical (GMED) alongside its peers. It outlines the industry's balance of steady demand with high innovation and regulatory costs, noting recurring revenue from consumables and services. The piece discusses demographic tailwinds and pricing pressures but does not provide specific financial figures or guidance for GMED. Consequently, it offers a broad, neutral assessment of the sector without material implications for GMED’s valuation.
What did this article say?
Globus Medical’s stock price of $74.08 appears to be trading at a discount relative to its earnings power, prompting analysts to question whether the company’s recent gains are sustainable or merely a result of a high multiple. The firm’s 45.9% return over three years has left holders with material gains, but the focus now shifts to how efficiently it converts procedure volume into margins and cash flow. Analysts have modeled the stock’s intrinsic value and suggest that the current price may not fully reflect the company’s earnings potential.
What did this article say?
Globus Medical (GMED) received a Zacks Rank #1 (Strong Buy) upgrade, driven by a bullish revision of earnings estimates. The rating reflects heightened confidence in the company’s near‑term profitability and is expected to support buying pressure. The upgrade signals that analysts anticipate continued earnings growth, potentially lifting the stock price.

Technical Analysis

Real-time indicators across multiple timeframes

55
NEUTRAL
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Congressional Trading Activity
4 disclosed trades · ~$56.5K est. traded value · 1 buys, 3 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▲ Buy$15K - $50K2026-08-192026-09-10
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-07-102025-08-13
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-04-092025-05-14
Thom TillisSenateNC▼ Sell$1K - $15K2015-02-132015-02-26